Table 1 Information related to the 76 study participants.

	Single assessment			Assessed twice 12 months apart			Total
		SD	Range		SD	Range		SD	p Value
Number of participants	33			43			76
Gender: male %	45.5			53.5			50		0.64
Diabetes: % taking drugs	5.9			4.9			5.3		1.0
Late‐onset FRDA: % with first symptom >25 years	9.1			16.3			13.2		0.50
Antioxidant use: % taking regular treatment	54.5			41.9			47.4		0.36
GAA2 mean: repeat number	911	152.7	658–1245	952.1	155.7	548–1345	934.9	154.7	0.026
GAA1 mean: repeat number	708.9	194.3	126–1005	646.8	212.4	284–1077	672.8	206	0.20
Age at initial examination: mean (years)	29.6	13.5	9–62	32.2	12.5	10–57	31.1	12.9	0.42
Age of onset: mean (years)	13.6	7.5	4–39	15.5	6.8	4–33	14.7	7.1	0.27
Disease duration: mean (years)	16.2	11.1	1.1–39.4	16.7	10.6	2–44.8	16.5	10.8	0.83
FARS: mean score	86.6	31.7	29.0–126.5	75.1	27.6	20.8–124.5	80.1	29.8	0.10
ICARS: mean score	53.5	21.7	14–82	47.5	19.2	15–80	50.1	20.4	0.20
FIM: mean score	100.5	20.5	63–125	112.4	13	75–126	107.6	17.7	<0.01
MBI: mean score	72.7	23.4	34–100	83.6	16.4	33–100	79.2	20.1	0.02

FARS, Friedreich Ataxia Rating Scale; FIM, Functional Independence Measure; FRDA, Friedreich's ataxia; GAA1, the size of the smaller of the two GAA expansions; GAA2, the size of the larger of the two GAA expansions; ICARS, International Cooperative Ataxia Rating Scale; MBI, Modified Barthel Index.

The p value is the significant difference between those seen once and those seen twice, 12 months apart.